REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.08
-0.30 (-3.20%)
Mar 12, 2026, 4:00 PM EDT - Market closed
REGENXBIO Revenue
In the year 2025, REGENXBIO had annual revenue of $170.44M with 104.54% growth. REGENXBIO had revenue of $30.34M in the quarter ending December 31, 2025, with 43.00% growth.
Revenue (ttm)
$170.44M
Revenue Growth
+104.54%
P/S Ratio
2.75
Revenue / Employee
$459,410
Employees
371
Market Cap
468.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.44M | 87.11M | 104.54% |
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Assembly Biosciences | 37.19M |
| Entrada Therapeutics | 25.42M |
| Aclaris Therapeutics | 7.83M |
| Altimmune | 41.00K |
RGNX News
- 1 day ago - Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals - Benzinga
- 1 day ago - Regenxbio's Duchenne gene therapy shows improved muscle function in trial - Reuters
- 1 day ago - REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire
- 6 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 7 days ago - REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - PRNewsWire
- 8 days ago - REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - PRNewsWire
- 9 days ago - REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire